Cabozantinib

Drug identity checked against registry records

Also recorded as Cabometyx; Cabometyx®; XL-184; XL184

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225ExelixisPhase 2Completed2013-05Actual
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791ExelixisPhase 3Active not recruiting2021-11-30Actual
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseNCT01068782ExelixisPhase 2Terminated2011-05Actual
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT07011719RCUSPhase 3Recruiting2028-04Estimated
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219ExelixisPhase 3Active not recruiting2022-01-31Actual
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574ExelixisPhase 3Enrolling by invitation2030-05-31Estimated
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117ExelixisPhase 3Active not recruiting2024-04-19Actual
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388ExelixisPhase 3Active not recruiting2020-08-19Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.